Insider · CIK 0001802615
Christophe Arbet-Engels
Files at ALT (Altimmune, Inc.), XFOR (X4 Pharmaceuticals, Inc). First filing Jan 27, 2025, latest Jan 27, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XFOR: X4 Pharmaceuticals, Inc
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | X4 Pharmaceuticals, Inc | $5,284 11,624 shares | -45% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | ALT Altimmune, Inc. | MOption exercise Common Stock, par value $0.0001 | +37,500 | $0.00 | $0 | 37,500 | 7 d ago |
| Oct 1, 2026 | ALT Altimmune, Inc. | FTax withholding Common Stock, par value $0.0001 | -12,679 | $2.76 | $35k | 24,821 | 7 d ago |
| Oct 1, 2026 | ALT Altimmune, Inc. | MOption exercise Restricted Stock Unitsderivative | -37,500 | $0.00 | $0 | 112,500 | 7 d ago |
| Oct 1, 2025 | ALT Altimmune, Inc. | AGrant or award Stock Options (option to buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Oct 3, 2025 |
| Oct 1, 2025 | ALT Altimmune, Inc. | AGrant or award Restricted Stock Unitsderivative | +150,000 | $0.00 | $0 | 150,000 | Oct 3, 2025 |
| Feb 12, 2025 | XFOR X4 Pharmaceuticals, Inc | AGrant or award Common Stock | +850,000 | $0.00 | $0 | 864,207 | Feb 14, 2025 |
| Jan 23, 2025 | XFOR X4 Pharmaceuticals, Inc | AGrant or award Common Stock | +25,831 | $0.00 | $0 | 25,831 | Jan 27, 2025 |
| Jan 24, 2025 | XFOR X4 Pharmaceuticals, Inc | SOpen-market sale Common Stock10b5-1 | -11,624 | $0.45 | $5,284 | 14,207 | Jan 27, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.